Metastatic malignant melanoma
Not recruitingStudy on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy
Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy
- Disease:Metastatic malignant melanoma
- Substances:DacarbazineIpilimumab+2
Germany- Participants:18–64 years · 65+ years
- Substances:Dacarbazine
- Sponsor:Universitaetsklinikum Erlangen AöR











